Your browser doesn't support javascript.
loading
A Multicenter Phase II, Double-Blind, Placebo-Controlled Trial of Maintenance Ixazomib After Allogeneic Transplantation for High-Risk Multiple Myeloma: Results of the Blood and Marrow Transplant Clinical Trials Network 1302 Trial.
Bashir, Qaiser; Nishihori, Taiga; Pasquini, Marcelo C; Martens, Michael J; Wu, Juan; Alsina, Melissa; Anasetti, Claudio; Brunstein, Claudio; Dawson, Peter; Efebera, Yvonne; Gasparetto, Cristina; Geller, Nancy; Giralt, Sergio; Hall, Aric C; Koreth, John; McCarthy, Philip; Scott, Emma; Stadtmauer, Edward A; Vesole, David H; Hari, Parameswaran.
Afiliação
  • Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: qbashir@mdanderson.org.
  • Nishihori T; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center. Tampa, Florida.
  • Pasquini MC; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Martens MJ; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
  • Wu J; Biostatistics Department, The Emmes Company, Rockville, Maryland.
  • Alsina M; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center. Tampa, Florida.
  • Anasetti C; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center. Tampa, Florida.
  • Brunstein C; Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
  • Dawson P; Biostatistics Department, The Emmes Company, Rockville, Maryland.
  • Efebera Y; Biostatistics Department, The Ohio State University & Ohio Health Blood and Marrow Transplant, Columbus, Ohio.
  • Gasparetto C; Department of Medicine, Duke University, Durham, North Carolina.
  • Geller N; Office of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
  • Giralt S; Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Hall AC; Department of Medicine, University of Wisconsin, Madison, Wisconsin.
  • Koreth J; Stem Cell Transplantation, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • McCarthy P; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
  • Scott E; Clinical Research Hematology/Oncology, The Janssen Pharmaceutical Companies of Johnson & Johnson, United States.
  • Stadtmauer EA; Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Vesole DH; Myeloma Division, John Theurer Cancer Center at Hackensack Meridian School of Medicine, Hackensack, New Jersey.
  • Hari P; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Transplant Cell Ther ; 29(6): 358.e1-358.e7, 2023 06.
Article em En | MEDLINE | ID: mdl-35840087
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Enxerto-Hospedeiro / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença Enxerto-Hospedeiro / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article